Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Northpond Ventures, founded by Michael P. Rubin, M.D., Ph.D., CFA, operates from Bethesda, Maryland, and Cambridge, Massachusetts. The firm focuses on advancing science and technology to address significant health challenges. It is recognized as one of the most active lead investors in the life sciences sector.
Northpond Ventures invests in biotechnology, diagnostics, digital health, and emerging technologies. They target a wide range of disease categories, including cardiology, oncology, and rare diseases, with check sizes typically ranging from seed to Series B.
Notable portfolio companies include MASS (NASDAQ: MASS), CAMP (NASDAQ: CAMP), CADL (NASDAQ: CADL), and several companies that have been acquired such as Best Buy, Paradigm Health, and Eli Lilly.
Email your pitch deck to contact@npv.vc for consideration.
Northpond Ventures focuses on biotechnology, diagnostics, and digital health, investing in companies that address critical health challenges across various disease categories.
Yes, Northpond Ventures is recognized as one of the most active lead investors in the life sciences sector.
The firm prefers companies in biotechnology, diagnostics, and digital health that are working on solutions for diseases such as oncology, cardiology, and rare genetic disorders.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.